Santa Clara
Family Health Plan

Regular Meeting of the
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan
Pharmacy & Therapeutics Committee
Thursday, September 21, 2017
6:00 PM - 8:00 PM
210 E. Hacienda Avenue Campbell, CA 95008

AGENDA

1.	**Introductions** a. Introduction of New Committee members: Dolly Goel, MD and Xuan Cung, PharmD b. Brown Act Meeting Requirements	Dr. Robertson	6:00	10 min.
2.	**Meeting Minutes** Review SCFHP 2Q2017 P&T Minutes (06.15.2017) **Possible Action:** Approve 06/15/2017 minutes	Dr. Lin	6:10	5 min.
3.	**Public Comment** Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes.	Dr. Lin	6:15	5 min.
4.	**Informational Updates**			
	a. CMO Health Plan Updates & Membership	Dr. Robertson	6:20	5 min.
	b. Pharmacy Dashboard	Dr. Otomo	6:25	5 min.
	c. MTM Oversight (2017Q1 & 2017Q2)	Dr. Otomo	6:30	5 min.
	d. Appeals & Grievances	Mr. Breakbill	6:35	5 min.
	e. Emergency Rx Access Monitoring	Dr. Huynh	6:40	1 min.
	Adjourn to Closed Session Pursuant to Welfare and Institutions Code Section 14087.36 (w)			
5.	**Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria**			
	a. MedImpact 2Q2017 P&T Meetings Minutes	Dr. Huynh	6:41	2 min.
	b. MedImpact 3Q2017 P&T Part D Actions **Possible Action:** Approve MedImpact minutes & actions	Dr. Huynh	6:43	2 min.
6.	**Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria**			
	a. Formulary Modifications **Possible Action:** Approve formulary recommendations	Dr. Otomo	6:45	5 min.
	b. Prior Authorization Criteria	Dr. Otomo	6:50	10 min.

Santa Clara
Family Health Plan

Reauthorization – Opioids
Hepatitis C
Tymlos (abaloparatide)
Adapalene (Differin)
Proventil HFA (albuterol sulfate)
Calcipotriene (Dovonex)
Darifenacin (Enablex)
Glatopa (glatiramer acetate)
Modafinil (Provigil)
Nicotine inhaler/nasal spray (Nicotrol/Nicotrol NS)
Lovaza (omega-3-Acid Ethyl Esters)
Elmiron (pentosan polysulfate sodium)
Lyrica (pregabalin)
Testosterone gel (Androgel)
Tetrabenazine (Xenazine)

Possible Action: Approve prior authorization criteria

c.	DHCS Medi-Cal CDL Updates & Comparability	Dr. McCarty	7:00	5 min.

Possible Action: Approve formulary recommendations

d.	New Drugs and Class Reviews	Dr. McCarty	7:05	15 min.

Factor Xa inhibitor – *(abbreviated)*
Bevyxxa (betrixaban)
Chronic Obstructive Pulmonary Disease – *(abbreviated)*
Trelegy Ellipta (umeclidinium/vilanterol/fluticasone)
Plaque Psoriasis - *(abbreviated)*
Tremfya (guselkumab)
Hepatitis C
Vosevi (sofosubvir/velpatasvir/voxilaprevir)
Mavyret (glecaprevir/pibrentasvir)
Glaucoma
Vyzulta (latanoprostene bunod)
Rhopressa (netarsudil)
Roclatan (netarsudil/latanoprost)
Attention-Deficit/Hyperactivity Disorder
Atomoxetine
Ampthetamine-dextroamphetamine extended-release
Methylphenidate extended-release
Dexmethylphenidate

Possible Action: Approve formulary recommendations

e.	Drug Utilization and Spend Review	Dr. McCarty	7:30	10 min.

Reconvene in Open Session

7.	**Discussion Items**			
a.	P&T Charter	Dr. Liu	7:40	5 min.
b.	Pharmacy Policies Update	Dr. Huynh	7:45	5 min.

Santa Clara
Family Health Plan

	Possible Action: Approve policies			
c.	Update on New Drugs and Generic Pipeline	Dr. McCarty	7:50	10 min.

8. Adjournment Dr. Lin 8:00

Next Meeting: Thursday, December 14, 2017

Membership

	2017-03	2017-04	2017-05	2017-06	2017-07	2017-08
AM	103	105	105	104	104	N/A
HK	2,752	2,794	2,757	2,732	2,633	2,618
MC	267,437	267,199	265,711	265,649	261,287	262,871
CMC	7,622	7,567	7,545	7,543	7,525	7,405
Grand Total	**277,914**	**277,665**	**276,118**	**276,028**	**271,549**	**272,894**

Previous Quarter Claim Count

Approved & Denied Claims – Q2 2017

Carrier HQ Code	Approved Claim Count	Denied Claim Count
SAC01	549,455	229,922
SAC02	1,086	1,557
SAC06	79,550	34,778
Summary	**630,091**	**266,257**

Approved & Denied Claims – Q1 2017

Carrier HQ Code	Approved Claim Count	Denied Claim Count
SAC01	542,526	240,202
SAC02	953	1,458
SAC06	79,836	34,506
Summary	**623,315**	**276,166**

Top 10 Requested Prior Authorizations YTD
Receipt Date: 1/1/2017 - 8/31/2017

SAC01 - Medi-Cal			
	Brand Name		**Formulary Status**
1	LYRICA		F w/ PA
2	HUMALOG KWIKPEN U-100		F w/ PA
3	XARELTO		F w/ PA
4	TRETINOIN		F w/ ST
5	DICLOFENAC SODIUM		NF
6	LIDOCAINE		NF
7	OXYCODONE HCL ER		F w/ PA
8	RESTASIS		F w/ PA
9	HUMIRA PEN		F w/ PA
10	JANUVIA		F w/ ST

Comments:
LIDOCAINE included: - Lidocaine 5% patches - Lidocaine 5% ointment - Lidocaine 5% cream
DICLOFENAC SODIUM included: - Diclofenac 1% gel - Diclofenac 3% gel - Diclofenac DR 75mg tab - Diclofenac 1.5% topical solution

SAC02 - Healthy Kids			
	Brand Name		**Formulary Status**
1	TRETINOIN		F w/ ST
2	TACROLIMUS OINT		NF
3	TRANEXAMIC ACID		NF
4	METHYLPHENIDATE ER (GENERIC CONCERTA)		F w/ ST
5	PROMACTA		NF
6	SYMBICORT		F w/ ST
7	AZITHROMYCIN TAB		F w/ QL
8	ELIDEL		F w/ PA
9	CANASA		NF
10	CLOBETASOL PROPIONATE OINT		NF

Comments:
TACROLIMUS included: - Tacrolimus 0.1% ointment - Tacrolimus 0.03% ointment

Q1-Q2 2017: Medi-Cal Appeals



Santa Clara Family Health Plan
The Spirit of Care

Q2 2017 Medi-Cal Pharmacy Appeals



Q2 2017: Part C&D Appeals



CMC Part D Redeterminations by Determination Q2 2017



Santa Clara
Family Health Plan

Santa Clara County Health Authority

Pharmacy and Therapeutics Committee Charter

Purpose

The Pharmacy and Therapeutics (P&T) Committee shall provide oversight of the Santa Clara Family Health Plan (SCFHP) pharmacy program to promote safe, efficacious, and cost-effective drug therapies through policies, formularies, and clinical criteria.

The P&T Committee reports to the Quality Improvement Committee (QIC). Signed minutes of the Committee are presented to the QIC by the Chair or designee.

Members

The Pharmacy and Therapeutics (P&T) Committee shall have a sufficient number of members to provide the necessary expertise and work effectively as a group. Membership shall include physicians and pharmacists with a specialty mix that reflects the medical needs of the populations of the SCFHP membership, including a pediatrician, a community based pharmacist, and a psychiatrist or other prescribing behavioral health practitioner.

All P&T members, including the Chairperson, shall be appointed by the Health Plan's Chief Executive Officer (CEO). All P&T members, including the Chairperson, can serve up to three two-year terms. Additional terms may be appointed at the discretion of the CEO, provided that the member is in compliance with the requirements set forth in this charter.

No person who holds a direct financial interest in an affiliated health care entity is eligible for appointment. P&T Committee members shall annually sign a Confidentiality, Conflict of Interest, and Non-Discrimination Agreement. Failure to sign the agreement or abide by the terms of the agreement shall result in removal from the committee.

Meetings

Regular meeting of the P&T Committee shall be scheduled quarterly. Additional special meetings, or meeting cancellations, may occur as circumstances dictate. Committee members must attend at least two meetings per year. Attendance may be in person or via teleconferencing. Teleconferencing shall be conducted pursuant to California Government Code section 54953(d). The presence of a majority of voting members shall constitute a quorum for the transaction of business.

The Committee may request other individuals, such as members of management, auditors, or other technical experts to participate in meetings and provide pertinent information relating to an agenda item, as necessary.

Meetings of the P&T Committee shall be open and public pursuant to the Ralph M. Brown Act (Gov. Code § 54950 et seq.)

Responsibilities

The following goals and objectives shall serve as a guide with the understanding that the Committee may carry out additional functions as may be appropriate in light of changing business, regulatory, legal and other conditions:

1. Review pharmacy department policies annually and changes as needed.
2. Review of therapeutic drug classes, standards of practice, peer review medical literature, and clinical practice guidelines.
3. Provide oversight of the plan's formulary development and maintenance.
4. Oversee the development and maintenance of clinical criteria for prior authorization.
5. Verify that the pharmacy department functions meet the standards and requirements of regulatory and licensing bodies.
6. Review utilization reports for patterns of under and over utilization.
7. Promote the delivery of quality patient care in an efficient and cost effective manner.

Duration of Charter

The Director of Pharmacy, SCFHP, will review this charter annually from the date of approval.

CY Version	Change (Original/ Reviewed / Revised)	Reviewing Director of Pharmacy	Director of Pharmacy Review Date	Reviewing Committee (if applicable)	Committee Action/Date (Recommend or Approve)
2017	**Revised**	**Johanna Liu, PharmD, MBA**	**09/05/2017**	**Pharmacy & Therapeutics Committee**	

POLICY

Santa Clara
Family Health Plan

Policy Title:	**340B Program Compliance**	**Policy No.:**	PH11
Replaces Policy Title (if applicable):		**Replaces Policy No. (if applicable):**	
Issuing Department:	Pharmacy	**Policy Review Frequency:**	Annually
Lines of Business (check all that apply):	☒ Medi-Cal ☒ Healthy Kids		☐ CMC

I. Purpose

To outline the requirements of Santa Clara Family Health Plan (SCFHP) Pharmacy Department's processes for complying with Federal and State 340B regulations.

II. Policy

A. SCFHP Pharmacy Department will comply with all requirements and restrictions of the Public Health Service Act Section 340B pertaining to a managed care organization (MCO) and the prohibition against duplicate discount/rebates under Medicaid pertaining.
B. The department will work with the Finance and Information Technology Departments to ensure the Department of Health Care Services 340B data reporting requirements are met [Patient Protection and Affordable Care Act of 2010, Public Law 111-148].

III. Responsibilities

A. Director of Pharmacy, or designee, will maintain knowledge of regulation and policy changes that impact 340B program including, but not limited to, Health Resources & Service Administration/Office of Pharmacy Affairs rules.
B. Director of Pharmacy, or designee, with the Pharmacy Benefit Manager (PBM) will ensure claims system availability of National Council for Prescription Drug Programs (NCPDP) Submission Clarification code 20 for 340B eligibility claim identification [California's W&I Code Section 14105.46].
C. Directory of Pharmacy, or designee, with the PBM will assist the Finance Department integrity audits.

IV. References

1. Section 340B of the Public Health Service Act.
2. Health Resources and Services Administration, Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Duplicate Discounts and Rebates on Drug Purchases, 58 Fed Reg. 27293 (May 7, 1993).
3. State Plan under Title XIX of the Social Security Act State: California. Methods and Standards for Establishing Payment Rates –Prescribed Drugs. Supplement 2 to Attachment 4. 19-B. TN No. 09-21B. (January 30, 2014).
4. National Council for Prescription Drug Programs, Inc. 340B Information Exchange. Reference Guide Version 1.0. July 2011.

V. Approval/Revision History

First Level Approval	Second Level Approval
[signature on file]	**[signature on file]**
Signature	Signature
Johanna Liu, PharmD	Jeff Robertson, MD
Name	Name
Director of Quality and Pharmacy	Chief Medical Officer
Title	Title
08/08/2017	09/11/2017
Date	Date

Version Number	Change (Original/ Reviewed/ Revised)	Reviewing Committee (if applicable)	Committee Action/Date (Recommend or Approve)	Board Action/Date (Approve or Ratify)
1	**Original**	**Pharmacy & Therapeutics Committee**		

POLICY

Santa Clara
Family Health Plan

Policy Title:	**Medications for Cancer Clinical Trial**	**Policy No.:**	PH14
Replaces Policy Title (if applicable):		**Replaces Policy No. (if applicable):**	
Issuing Department:	Pharmacy	**Policy Review Frequency:**	Annually
Lines of Business (check all that apply):	☒ Medi-Cal ☐ Healthy Kids		☐ CMC

I. Purpose

To define the process that provides prescription drug coverage to members diagnosed with cancer and accepted into a phase I, phase II, phase III, or phase IV clinical trial for cancer with therapeutic intended endpoints and not exclusively defined to test toxicity.

II. Policy

A. SCFHP shall define the process for coverage of routine patient care costs related to the clinical trial, including drugs that would otherwise be covered under the plan if those drugs were not provided in connection with an approved clinical trial program.
B. Routine patient care costs does not include the costs associated with the provision of:
    a. Drugs or devices that have not been approved by the federal Food and Drug Administration (FDA) and that are associated with the clinical trial.
C. The plan shall provide coverage of routine patient care costs, including other drug coverage given that the cancer clinical trial involves a drug that is exempt under federal regulations from a new drug application or approved by one of the following:
    a. National Institutes of Health (NIH);
    b. The federal FDA, in the form of an investigational new drug application;
    c. Department of Defense; or
    d. Veterans' Administration.
D. The plan may restrict coverage for clinical trials to participating hospitals and physicians if the protocol for the clinical trial is not provided.

III. Responsibilities

A. Director of Pharmacy, or designee, will ensure medications for cancer clinical trial members are processed in the appropriate timeframe.

IV. References

1. Health and Safety Code Section 1370.6
2. Welfare and Institutions Code Sections 14087.11, 14132.98, and 1412.99.
3. Senate Bill 37, Chapter 172, Amended March 13, 2001.

V. Approval/Revision History

First Level Approval	Second Level Approval
[signature on file]	**[signature on file]**
Signature Johanna Liu, PharmD	Signature Jeff Robertson, MD
Name Director of Quality and Pharmacy	Name Chief Medical Officer
Title 09/05/2017	Title 09/13/2017
Date	Date

Version Number	Change (Original/ Reviewed/ Revised)	Reviewing Committee (if applicable)	Committee Action/Date (Recommend or Approve)	Board Action/Date (Approve or Ratify)
1	**Original**	**Pharmacy & Therapeutics Committee**		

High Interest and Impact Pipeline Agents

2H2017

Entity	Disease State	Anticipated FDA Decision	Route
romosozumab	Osteoporosis	July 19th, 2017	SQ* *Update – FDA issued Complete Response Letter*
Kymriah (tisagenlecleucel-T)	Pediatric Acute Lymphoblastic Leukemia (ALL)	September 29th, 2017	IV *Update – Approved 8/30/17, Launched 9/11/17*
Shingrix (shingles vaccine)	Herpes zoster vaccine	October 2017	IM*
KTE-C19 (axicabtagene ciloleucel)	Non-Hodgkin Lymphoma (NHL)	November 29th, 2017	IV

= Medical Cost

Generic Pipeline 3Q17

HIGH IMPACT



2017
Tracleer*

July 2017
Safyral
Ziagen (oral soln)

Aug 2017
Effient

3Q2017
Uceris tablet
Aloxi*

Sept 2017
Estrace cream

Oct 2017
Byetta

Nov 2017
Adcirca

2017 - 2018
Androgel (1.62% pkt)
Androgel (1.62% pump)
Kaletra tablets
Norvir capsules
Sustiva

2018
Copaxone 40mg/mL*
Proventil HFA

MEDIUM /LOW IMPACT

**NO exclusivity*